Mergers & Acquisitions ·
Quince Therapeutics sells Italian subsidiary and AIDE IP to Ayma Therapeutics for $450,000 as President Charles Ryan departs with $1.01M severance
QNCXIRulya Therapeutics Inc.
Quince Therapeutics completed the sale of its Italian subsidiary, Quince SpA, along with specific intellectual property related to its AIDE technology for Ataxia-Telangiectasia and associated equipment, to Ayma Therapeutics for $450,000 in cash. Concurrently, President Charles Ryan departed effective September 8, 2026, receiving a lump-sum severance payment of approximately $1.01 million under his executive agreement. The company operates in the biotechnology industry.